Opendata, web and dolomites

TALVIN SIGNED

Inhibiting mechanotransduction for the treatment of pancreatic cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TALVIN" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA 

Organization address
address: CARRER BALDIRI REIXAC PLANTA 2A 10-12
city: BARCELONA
postcode: 8028
website: http://www.ibecbarcelona.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 100˙000 €
 EC max contribution 100˙000 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-4-2016-2017
 Funding Scheme CSA
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES (BARCELONA) coordinator 100˙000.00

Map

 Project objective

Mechanical forces transmitted between cells and their microenvironment drive cell function and regulate tumorigenesis. Due to this importance, our FET PROACTIVE project MECHANOCONTROL aims to understand the molecular mechanisms by which forces exert their role, and their implications in the specific application of breast cancer. In this context, we have recently identified that the interaction between the cytoskeletal molecules vinculin and talin can be inhibited by a vinculin fragment (VD1) which blocks cell response to mechanical forces, and the activation of the major oncogene YAP that occurs in tissues with abnormally high mechanical stiffness. Both increased tissue stiffness and YAP activation drive tumor progression in most solid tumors, and thus inhibiting talin/vinculin interactions has a major potential as a therapeutic approach in several solid cancer types. We have designed and synthesized peptido-mimetic drugs reproducing the action of VD1. Among those synthesized, we have identified one that inhibits the metabolism of cell lines from pancreatic, colon and prostate tumors. Our aim is to valorize these drugs in the specific case of pancreatic cancer, which is a clear unmet clinical need since it is the one with the least therapeutic alternatives and worst prognosis. Specifically, the funding from this project will pay for the national phases of the current patent (PCT/EP2017/056410), regulatory pharmacokinetics/pharmacodynamics and toxicity tests in mouse animal models, as well as for developing contacts of potential license-takers to close a license agreement. Because the focus is on pancreatic rather than breast cancer, and on bringing a specific drug to the market rather than carrying out research, this project is related to but falls out of the scope of the FET MECHANOCONTROL project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TALVIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TALVIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

FETFX (2019)

Stimulating effects of Future and Emerging Technologies through communication and outreach

Read More